ARTICLE | Clinical News
MLNM Velcade interim Phase II NHL data
June 14, 2005 1:40 AM UTC
Millennium (MLNM) said that in a Phase II trial to treat indolent non-Hodgkin's lymphoma (NHL), response rates in 34 evaluable patients given weekly or twice weekly Velcade bortezomib plus Rituxan rit...